Related Experiment Video

Updated: Aug 10, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.1K

Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival

Juhua Luo1, Michael Hendryx2, Yi Dong3,4

  • 1Department of Epidemiology and Biostatistics, School of Public Health, Indiana University, Bloomington, IN, USA. juhluo@indiana.edu.

British Journal of Cancer
|February 10, 2023
PubMed
Abstract

Insights

Sodium-glucose cotransporter 2 (SGLT2) inhibitors may improve survival in non-small cell lung cancer (NSCLC) patients with diabetes. This study found SGLT2 inhibitor use linked to reduced mortality risk in this patient group.

Area of Science:

  • Oncology
  • Pharmacology
  • Epidemiology

Background:

  • Sodium-glucose cotransporter 2 (SGLT2) inhibitors are antidiabetic drugs with known benefits for renal and cardiovascular diseases.
  • The potential impact of SGLT2 inhibitors on cancer survival is an emerging area of research.

Purpose of the Study:

  • To evaluate the association between SGLT2 inhibitor use and overall survival in patients with non-small cell lung cancer (NSCLC) and pre-existing diabetes.
  • To investigate if SGLT2 inhibitor use influences mortality risk in NSCLC patients.

Main Methods:

  • Utilized SEER-Medicare linked data for a cohort of 24,915 NSCLC patients diagnosed between 2014-2017.
  • Included patients aged 66+ with pre-existing diabetes, followed through 2019.
  • Extracted SGLT2 inhibitor use data from Medicare Part D files.

Main Results:

  • SGLT2 inhibitor use was significantly associated with reduced mortality risk (HR=0.68).
  • Longer duration of SGLT2 inhibitor use showed a stronger association with reduced mortality (HR=0.54).
  • The reduced risk of mortality was consistent across various patient demographics, tumor characteristics, and cancer treatments.

Conclusions:

  • SGLT2 inhibitor use is associated with improved overall survival in NSCLC patients with diabetes.
  • Further research is warranted to confirm these findings and explore the underlying mechanisms.

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

Related Concept Videos

Secondary Active Transport01:55

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
122.3K
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
23.9K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
252
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
408
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K